Product Description
HN0037 is a helicase-primase inhibitor developed to treat herpes simplex virus (HSV) infection. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/35794079/)
Mechanisms of Action: WRN Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huinuo Biomedical Technology (Hangzhou) Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Herpes Labialis|Herpes Simplex
Phase 1: Herpes Simplex
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2100043672 |
ChiCTR2100043672 | N/A |
Recruiting |
Herpes Simplex |
2022-03-31 |
|||
CTR20210378 |
CTR20210378 | P1 |
Completed |
Herpes Simplex |
2022-01-02 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20253323 |
CTR20253323 | P2 |
Unknown |
Herpes Labialis |
None |
2025-12-06 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20252614 |
CTR20252614 | P2 |
Unknown |
Herpes Simplex |
None |
2025-11-23 |
Patient Enrollment|Treatments|Trial Status |